Acrivon Therapeutics (ACRV) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Intercure (INCR) over the past year, losing 0.5% versus a loss of 37.5%. Acrivon Therapeutics is the larger company by market cap ($80.1 million vs $75.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | INCR |
|---|---|---|
| Share price | $1.87 | $5.02 |
| Market cap | $80.14M | $75.32M |
| 1-day change | 0.00% | 0.00% |
| YTD return | -22.41% | +10.55% |
| 1-year return | -0.53% | -37.52% |
| 5-year return | — | -85.81% |
| EPS (TTM) | $-1.88 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $8.40 |
| 52-week low | $1.27 | $3.40 |
| Distance from 52-week high | -47.47% | -40.24% |
| Analyst consensus | none | — |
| Avg. price target upside | +514.97% | — |
| Average volume | 356.18K | 21.73K |
| Shares outstanding | 42.85M | 15.00M |
| Employees | 74 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed INCR by 37.0 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
ACRV vs INCR FAQ
Which is bigger, Acrivon Therapeutics or Intercure?
Acrivon Therapeutics (ACRV) is larger, with a market capitalization of $80.14M compared with $75.32M for Intercure (INCR).
Which stock has performed better over the past year, ACRV or INCR?
ACRV returned -0.53% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Intercure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.